S&P 500   4,305.34 (+0.27%)
DOW   33,871.06 (+0.11%)
QQQ   354.64 (+0.42%)
AAPL   181.44 (+0.48%)
MSFT   327.33 (+0.64%)
META   264.99 (+0.15%)
GOOGL   122.53 (+0.32%)
AMZN   123.83 (-0.34%)
TSLA   246.69 (+5.04%)
NVDA   389.64 (+1.18%)
NIO   7.92 (+1.67%)
BABA   85.83 (-0.36%)
AMD   124.75 (+3.06%)
T   16.01 (-0.37%)
F   13.82 (+1.77%)
MU   65.29 (-0.05%)
CGC   0.67 (-3.31%)
GE   105.71 (-0.34%)
DIS   91.81 (-0.78%)
AMC   4.73 (+1.07%)
PFE   38.94 (-0.38%)
PYPL   63.53 (-1.11%)
NFLX   423.99 (+3.57%)
S&P 500   4,305.34 (+0.27%)
DOW   33,871.06 (+0.11%)
QQQ   354.64 (+0.42%)
AAPL   181.44 (+0.48%)
MSFT   327.33 (+0.64%)
META   264.99 (+0.15%)
GOOGL   122.53 (+0.32%)
AMZN   123.83 (-0.34%)
TSLA   246.69 (+5.04%)
NVDA   389.64 (+1.18%)
NIO   7.92 (+1.67%)
BABA   85.83 (-0.36%)
AMD   124.75 (+3.06%)
T   16.01 (-0.37%)
F   13.82 (+1.77%)
MU   65.29 (-0.05%)
CGC   0.67 (-3.31%)
GE   105.71 (-0.34%)
DIS   91.81 (-0.78%)
AMC   4.73 (+1.07%)
PFE   38.94 (-0.38%)
PYPL   63.53 (-1.11%)
NFLX   423.99 (+3.57%)
S&P 500   4,305.34 (+0.27%)
DOW   33,871.06 (+0.11%)
QQQ   354.64 (+0.42%)
AAPL   181.44 (+0.48%)
MSFT   327.33 (+0.64%)
META   264.99 (+0.15%)
GOOGL   122.53 (+0.32%)
AMZN   123.83 (-0.34%)
TSLA   246.69 (+5.04%)
NVDA   389.64 (+1.18%)
NIO   7.92 (+1.67%)
BABA   85.83 (-0.36%)
AMD   124.75 (+3.06%)
T   16.01 (-0.37%)
F   13.82 (+1.77%)
MU   65.29 (-0.05%)
CGC   0.67 (-3.31%)
GE   105.71 (-0.34%)
DIS   91.81 (-0.78%)
AMC   4.73 (+1.07%)
PFE   38.94 (-0.38%)
PYPL   63.53 (-1.11%)
NFLX   423.99 (+3.57%)
S&P 500   4,305.34 (+0.27%)
DOW   33,871.06 (+0.11%)
QQQ   354.64 (+0.42%)
AAPL   181.44 (+0.48%)
MSFT   327.33 (+0.64%)
META   264.99 (+0.15%)
GOOGL   122.53 (+0.32%)
AMZN   123.83 (-0.34%)
TSLA   246.69 (+5.04%)
NVDA   389.64 (+1.18%)
NIO   7.92 (+1.67%)
BABA   85.83 (-0.36%)
AMD   124.75 (+3.06%)
T   16.01 (-0.37%)
F   13.82 (+1.77%)
MU   65.29 (-0.05%)
CGC   0.67 (-3.31%)
GE   105.71 (-0.34%)
DIS   91.81 (-0.78%)
AMC   4.73 (+1.07%)
PFE   38.94 (-0.38%)
PYPL   63.53 (-1.11%)
NFLX   423.99 (+3.57%)
NASDAQ:AGIO

Agios Pharmaceuticals (AGIO) Stock Forecast, Price & News

$26.13
-0.47 (-1.77%)
(As of 01:20 PM ET)
Compare
Today's Range
$25.93
$26.71
50-Day Range
$21.38
$27.12
52-Week Range
$16.75
$34.76
Volume
76,326 shs
Average Volume
493,851 shs
Market Capitalization
$1.45 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$37.00

Agios Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
40.8% Upside
$37.00 Price Target
Short Interest
Bearish
10.86% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.54
Upright™ Environmental Score
News Sentiment
0.04mentions of Agios Pharmaceuticals in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$1.27 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($6.16) to ($5.19) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.87 out of 5 stars

Medical Sector

640th out of 986 stocks

Pharmaceutical Preparations Industry

305th out of 481 stocks


AGIO stock logo

About Agios Pharmaceuticals (NASDAQ:AGIO) Stock

Agios Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.

Receive AGIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Agios Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AGIO Stock News Headlines

All Electric Commitment From GM, Volkswagen, Could Put Lithium Sector In A Supercycle
More automakers are pledging to go "fully electric" by 2035. NOW is the perfect time to get in on the "EV Revolution." And the best way to potentially do that, is to skip over the overvalued electric vehicle stocks...
Agios Appoints Catherine Owen to Board of Directors
All Electric Commitment From GM, Volkswagen, Could Put Lithium Sector In A Supercycle
More automakers are pledging to go "fully electric" by 2035. NOW is the perfect time to get in on the "EV Revolution." And the best way to potentially do that, is to skip over the overvalued electric vehicle stocks...
Q1 2023 Agios Pharmaceuticals Inc Earnings Call
See More Headlines

AGIO Price History

AGIO Company Calendar

Last Earnings
5/04/2023
Today
6/09/2023
Next Earnings (Estimated)
8/03/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AGIO
Fax
N/A
Employees
390
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$37.00
High Stock Price Forecast
$41.00
Low Stock Price Forecast
$32.00
Forecasted Upside/Downside
+41.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

Net Income
$-231,800,000.00
Net Margins
-1,146.58%
Pretax Margin
-1,146.58%

Debt

Sales & Book Value

Annual Sales
$14.24 million
Book Value
$20.03 per share

Miscellaneous

Free Float
53,224,000
Market Cap
$1.45 billion
Optionable
Optionable
Beta
0.94

Key Executives

  • Brian M. Goff
    Chief Executive Officer & Director
  • Cecilia Jones
    Chief Financial Officer
  • Clive Patience
    Chief Technical Operations Officer
  • Sarah Gheuens
    Chief Medical Officer, Head-Research & Development
  • Charlie Newman
    Chief Business Officer













AGIO Stock - Frequently Asked Questions

Should I buy or sell Agios Pharmaceuticals stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Agios Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AGIO shares.
View AGIO analyst ratings
or view top-rated stocks.

What is Agios Pharmaceuticals' stock price forecast for 2023?

4 Wall Street research analysts have issued 12-month price targets for Agios Pharmaceuticals' stock. Their AGIO share price forecasts range from $32.00 to $41.00. On average, they expect the company's share price to reach $37.00 in the next twelve months. This suggests a possible upside of 41.9% from the stock's current price.
View analysts price targets for AGIO
or view top-rated stocks among Wall Street analysts.

How have AGIO shares performed in 2023?

Agios Pharmaceuticals' stock was trading at $28.08 on January 1st, 2023. Since then, AGIO shares have decreased by 7.2% and is now trading at $26.07.
View the best growth stocks for 2023 here
.

When is Agios Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our AGIO earnings forecast
.

How were Agios Pharmaceuticals' earnings last quarter?

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) issued its quarterly earnings data on Thursday, May, 4th. The biopharmaceutical company reported ($1.47) EPS for the quarter, topping the consensus estimate of ($1.72) by $0.25. The biopharmaceutical company earned $5.61 million during the quarter, compared to the consensus estimate of $5.23 million. Agios Pharmaceuticals had a negative trailing twelve-month return on equity of 20.23% and a negative net margin of 1,146.58%. The business's quarterly revenue was up 574.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($1.74) EPS.

What is Jackie Fouse's approval rating as Agios Pharmaceuticals' CEO?

11 employees have rated Agios Pharmaceuticals Chief Executive Officer Jackie Fouse on Glassdoor.com. Jackie Fouse has an approval rating of 100% among the company's employees. This puts Jackie Fouse in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Agios Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Agios Pharmaceuticals investors own include Gilead Sciences (GILD), Micron Technology (MU), Alibaba Group (BABA), bluebird bio (BLUE), Pfizer (PFE), Vertex Pharmaceuticals (VRTX), NVIDIA (NVDA), Tesla (TSLA) and Netflix (NFLX).

What is Agios Pharmaceuticals' stock symbol?

Agios Pharmaceuticals trades on the NASDAQ under the ticker symbol "AGIO."

Who are Agios Pharmaceuticals' major shareholders?

Agios Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Wellington Management Group LLP (10.30%), BlackRock Inc. (8.67%), Armistice Capital LLC (6.23%), State Street Corp (5.51%), Farallon Capital Management LLC (3.77%) and Dimensional Fund Advisors LP (3.76%). Insiders that own company stock include Carman Alenson, Christopher Bowden, Darrin Miles, David P Schenkein and Theodore James Jr Washburn.
View institutional ownership trends
.

How do I buy shares of Agios Pharmaceuticals?

Shares of AGIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Agios Pharmaceuticals' stock price today?

One share of AGIO stock can currently be purchased for approximately $26.07.

How much money does Agios Pharmaceuticals make?

Agios Pharmaceuticals (NASDAQ:AGIO) has a market capitalization of $1.45 billion and generates $14.24 million in revenue each year. The biopharmaceutical company earns $-231,800,000.00 in net income (profit) each year or ($3.97) on an earnings per share basis.

How many employees does Agios Pharmaceuticals have?

The company employs 390 workers across the globe.

How can I contact Agios Pharmaceuticals?

Agios Pharmaceuticals' mailing address is 88 SIDNEY STREET, CAMBRIDGE MA, 02139. The official website for the company is www.agios.com. The biopharmaceutical company can be reached via phone at (617) 649-8600 or via email at investors@agios.com.

This page (NASDAQ:AGIO) was last updated on 6/9/2023 by MarketBeat.com Staff

My Account -